Specific immune response and pathological findings in BALB/c mice inoculated with recombinant BCG expressing HIV-1 antigen.
暂无分享,去创建一个
P. Puthavathana | W. Wiriyarat | S. Sukpanichnant | M. Honda | K. Matsuo | R. Sutthent | N. Sittisombut | K. Balachandra | P. Warachit | D. Promkhatkaew | Raywadee Butraporn | Jotika Boonlong
[1] H. Kiyono,et al. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. , 2002, Vaccine.
[2] Oral recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. , 2002, Clinical immunology.
[3] J. Schneider-Mergener,et al. Identification of T helper cell-recognized epitopes in the chitinase of the filarial nematode Onchocerca volvulus. , 2002, Vaccine.
[4] H. Kiyono,et al. HIV Mucosal Vaccine: Nasal Immunization with rBCG-V3J1 Induces a Long Term V3J1 Peptide-Specific Neutralizing Immunity in Th1- and Th2-Deficient Conditions1 , 2001, The Journal of Immunology.
[5] C. Rouzioux,et al. Patient-Specific Cytotoxic T-Lymphocyte Cross-Recognition of Naturally Occurring Variants of a Human Immunodeficiency Virus Type 1 (HIV-1) p24gagEpitope by HIV-1-Infected Children , 2001, Journal of Virology.
[6] K. Ruxrungtham,et al. Safety and immunogenicity of Bacillus Calmette-Guerin vaccine in children born to HIV-1 infected women. , 2000, The Southeast Asian journal of tropical medicine and public health.
[7] R. Young,et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. , 2000, Vaccine.
[8] D. Birx,et al. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. , 1998, The Journal of infectious diseases.
[9] S. Matsumoto,et al. Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Secreting Merozoite Surface Protein 1 (MSP1) Induces Protection against Rodent Malaria Parasite Infection Depending on MSP1-stimulated Interferon γ and Parasite-specific Antibodies , 1998, The Journal of experimental medicine.
[10] P. Kaleebu,et al. Cross‐clade recognition of p55 by cytotoxic T lymphocytes in HIV‐1 infection , 1998, AIDS.
[11] J. Sterne,et al. Does the efficacy of BCG decline with time since vaccination? , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[12] B. Walker,et al. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development , 1997, Journal of virology.
[13] F. Oftung,et al. T-Cell epitope mapping the PorB protein of serogroup B Neisseria meningitidis in B10 congenic strains of mice. , 1997, Clinical immunology and immunopathology.
[14] S. Matsumoto,et al. A stable Escherichia coli-mycobacteria shuttle vector 'pSO246' in Mycobacterium bovis BCG. , 1996, FEMS microbiology letters.
[15] Y. Okamoto,et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[16] M. Hanson,et al. Efficacy and safety of live recombinant BCG vaccines. , 1995, Developments in biological standardization.
[17] S. Langermann,et al. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi , 1994, Nature.
[18] M. Hanson,et al. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A , 1994, The Journal of experimental medicine.
[19] K. Ikuta,et al. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. , 1994, Vaccine.
[20] M. Hanson,et al. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine , 1993, The Journal of experimental medicine.
[21] R. Young,et al. Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines , 1991, Nature.
[22] W. Jacobs,et al. New use of BCG for recombinant vaccines , 1991, Nature.
[23] K. Kobayashi,et al. Establishment of a foreign antigen secretion system in mycobacteria , 1990, Infection and immunity.
[24] T. Yamada,et al. Cloning and characterization of the gene for immunogenic protein MPB64 of Mycobacterium bovis BCG , 1989, Infection and immunity.
[25] I. Azuma,et al. Adjuvant activity of mycobacterial fractions. III. Adjuvant effect of cell wall of Mycobacterium bovis BCG on cell-mediated cytotoxicity in mice. , 1975, Japanese journal of microbiology.
[26] I. Azuma,et al. Adjuvant activity of mycobacterial fractions. I. Purification and in vivo adjuvant activity of cell wall skeletons of Mycobacterium bovis BCG, Nocardia asteroides 131 and Corynebacterium diphtheriae PW8. , 1975, Biken journal.